MX9301935A - Compuestos para el tratamiento de alteraciones neurodegenerativas. - Google Patents
Compuestos para el tratamiento de alteraciones neurodegenerativas.Info
- Publication number
- MX9301935A MX9301935A MX9301935A MX9301935A MX9301935A MX 9301935 A MX9301935 A MX 9301935A MX 9301935 A MX9301935 A MX 9301935A MX 9301935 A MX9301935 A MX 9301935A MX 9301935 A MX9301935 A MX 9301935A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- compounds
- neurodegenerative
- neurodegenerative disorders
- alterations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929207339A GB9207339D0 (en) | 1992-04-03 | 1992-04-03 | Pharmaceutical compound |
| GB929208290A GB9208290D0 (en) | 1992-04-15 | 1992-04-15 | Pharmaceutical compound having neuroprotective properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9301935A true MX9301935A (es) | 1994-08-31 |
Family
ID=26300643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9301935A MX9301935A (es) | 1992-04-03 | 1993-04-02 | Compuestos para el tratamiento de alteraciones neurodegenerativas. |
Country Status (28)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9320273D0 (en) * | 1993-04-01 | 1993-11-17 | Fisons Corp | Compound useful in therapy |
| EP0356035B1 (en) * | 1988-08-12 | 1996-03-13 | Astra Aktiebolag | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties |
| ZA942140B (en) * | 1993-04-01 | 1994-10-03 | Fisons Corp | Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901237D0 (sv) * | 1999-04-06 | 1999-04-06 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| ATE306482T1 (de) * | 1999-07-28 | 2005-10-15 | Ortho Mcneil Pharm Inc | Amine and amide als ligande für den neuropeptid-y y5 rezeptor, und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen |
| WO2007017652A2 (en) * | 2005-08-10 | 2007-02-15 | Astrazeneca Ab | Arylakylamines for the treatment of cancer |
| NZ593282A (en) * | 2008-12-24 | 2013-06-28 | Astrazeneca Ab | Ethanamine compounds and their use for treating depression |
| CN104114714A (zh) | 2011-12-14 | 2014-10-22 | 阿斯利康(瑞典)有限公司 | Gabr-a2诊断 |
| RS58991B1 (sr) * | 2013-11-05 | 2019-08-30 | Astrazeneca Ab | Prolekovi nmda antagonista |
| BR112022025900A2 (pt) * | 2020-06-23 | 2023-01-10 | Biohaven Therapeutics Ltd | Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0320006A3 (en) * | 1987-12-11 | 1990-12-19 | Laboratoires Syntex | Uses of 1,4-dihydropyridines |
| EP0356035B1 (en) * | 1988-08-12 | 1996-03-13 | Astra Aktiebolag | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties |
-
1993
- 1993-04-01 RU RU94042465A patent/RU2128650C1/ru active
- 1993-04-01 JP JP05517251A patent/JP3120810B2/ja not_active Expired - Lifetime
- 1993-04-01 DE DE69317411T patent/DE69317411T2/de not_active Expired - Lifetime
- 1993-04-01 KR KR1019940703465A patent/KR100259567B1/ko not_active Expired - Lifetime
- 1993-04-01 SG SG1996005610A patent/SG47948A1/en unknown
- 1993-04-01 CZ CZ19942409A patent/CZ288519B6/cs not_active IP Right Cessation
- 1993-04-01 AU AU38976/93A patent/AU3897693A/en not_active Abandoned
- 1993-04-01 NZ NZ251384A patent/NZ251384A/en not_active IP Right Cessation
- 1993-04-01 ES ES93907975T patent/ES2115055T3/es not_active Expired - Lifetime
- 1993-04-01 UA UA94095853A patent/UA29437C2/uk unknown
- 1993-04-01 SK SK1177-94A patent/SK281258B6/sk not_active IP Right Cessation
- 1993-04-01 EP EP93907975A patent/EP0633879B1/en not_active Expired - Lifetime
- 1993-04-01 PL PL93305404A patent/PL180014B1/pl unknown
- 1993-04-01 DK DK93907975T patent/DK0633879T3/da active
- 1993-04-01 AT AT93907975T patent/ATE163925T1/de active
- 1993-04-01 WO PCT/GB1993/000689 patent/WO1993020052A1/en not_active Ceased
- 1993-04-01 CA CA002133427A patent/CA2133427C/en not_active Expired - Lifetime
- 1993-04-02 MY MYPI93000602A patent/MY110149A/en unknown
- 1993-04-02 ZA ZA932415A patent/ZA932415B/xx unknown
- 1993-04-02 IL IL105276A patent/IL105276A/xx not_active IP Right Cessation
- 1993-04-02 MA MA23157A patent/MA22866A1/fr unknown
- 1993-04-02 MX MX9301935A patent/MX9301935A/es unknown
- 1993-04-03 DZ DZ930038A patent/DZ1677A1/fr active
- 1993-04-03 CN CN93104534A patent/CN1044367C/zh not_active Expired - Lifetime
- 1993-04-30 TW TW082103364A patent/TW282455B/zh not_active IP Right Cessation
-
1994
- 1994-09-30 FI FI944546A patent/FI105025B/fi not_active IP Right Cessation
- 1994-09-30 NO NO943645A patent/NO302170B1/no not_active IP Right Cessation
-
1995
- 1995-06-13 HU HU95P/P00192P patent/HU211529A9/hu unknown
-
1996
- 1996-12-18 AU AU75456/96A patent/AU705419B2/en not_active Expired
-
2000
- 2000-05-30 JP JP2000159319A patent/JP2000319259A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9304819A (es) | Nuevos derivados de xantina y procedimiento para su preparacion. | |
| SV1995000042A (es) | Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv | |
| PA8442001A1 (es) | Derivados de pirimidina biciclica condensada | |
| IT1254915B (it) | Derivati di adenosina ad attivita' a2 agonista | |
| ITMI931714A0 (it) | Uso del taxol per la produzione di un medicamento per il trattamento delle forme cancerose | |
| ES2161290T3 (es) | Derivados de quinazolina. | |
| ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| SV1998000029A (es) | Compuestos de pirazina ref. pg3186 | |
| MX9301935A (es) | Compuestos para el tratamiento de alteraciones neurodegenerativas. | |
| SV1999000048A (es) | Uso de dihidropiriminas como medicamento y nuevas sustancias ref. lea 32 791-sv | |
| AR006119A1 (es) | Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos | |
| ES2172937T3 (es) | 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides. | |
| ES2158876T3 (es) | Derivado de galantamina, un procedimiento para su preparacion y su utilizacion como medicamento. | |
| ATE131536T1 (de) | Fr-901154- und fr-901155-derivate, verfahren zu ihrer herstellung | |
| MXPA02006610A (es) | Sustancias para uso al tratar psoriasis. | |
| DK0579996T3 (da) | 5,10-Methylentetrahydrofolsyrecyclodextrin-inklusionsforbindelser | |
| ES2102043T3 (es) | Derivados de 22-en-25-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que los contienen, asi como su utilizacion en calidad de medicamentos. | |
| ES2167721T3 (es) | Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica. | |
| SV1998000023A (es) | Arilsulfonamidas y analogos ref. lea 32316-sv | |
| ATE137237T1 (de) | R-(-)-1-(5-hydroxyhexyl)-3-methyl-7- propylxanthin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel | |
| ITMI931019A1 (it) | Derivati del cicloeptimmidazolo, metodo per la loro produzione e agenti terapeutici contenenti questi composti | |
| ES2135500T3 (es) | Producto farmaceutico para el tratamiento de trastornos de la piel. | |
| NZ292388A (en) | S-enantiomers of 2-alkyl substituted pentynoic acid derivatives, preparation and pharmaceutical compositions thereof | |
| ATE243683T1 (de) | Polyhydroxybutylpyrazinen, deren herstellung und diese enthaltende arzneimitteln | |
| AR015190A1 (es) | Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento |